Overview
Tetrofosmin was developed to overcome the non-target uptake of radioligands by the generation of hetero-atomic compounds. It presents a molecular formula of 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane. Tetrofosmin is part of the group of diphosphines. Tetrofosmin is used in conjunction with technetium Tc-99m as a radiopharmaceutical.
Indication
Tetrofosmin is indicated to be used as a complex with technetium Tc-99m for scintigraphic imaging of the myocardium following separate administrations under exercise and/or resting conditions. It helps in the delineation of regions of reversible myocardial ischemia in absence of infarcted myocardium. This complex is also used for scintigraphic imaging of the myocardium to identify changes in perfusion induced by pharmacologic stress in patients with known or suspected coronary artery disease. This complex is indicated for the assessment of left ventricular function in patients evaluated for heart disease.
Associated Conditions
- Breast Cancer
- Hypoperfusion
- Myocardial Infarction
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|
No clinical trials found
No clinical trials found for this drug
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Medi-Physics Inc. dba GE Healthcare | 17156-024 | INTRAVENOUS | 0.23 mg in 1 1 | 12/12/2022 | |
| AnazaoHealth Corporation | 51808-223 | INTRAVENOUS | 0.35 mg in 1 1 | 7/2/2012 | |
| Medi-Physics Inc. dba GE Healthcare | 17156-026 | INTRAVENOUS | 1.38 mg in 1 1 | 12/12/2022 | |
| AnazaoHealth Corporation | 51808-223 | INTRAVENOUS | 0.35 mg in 1 1 | 7/3/2012 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| MYOVIEW FOR INJECTION 0.23 mg/vial | SIN11820P | INJECTION, POWDER, FOR SOLUTION | 0.23 mg/vial | 2/25/2002 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| MYOVIEW kit for the preparation of technetium [99cm Tc] tetrofosmin injection vial | 60998 | Medicine | A | 8/26/1997 |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| No Health Canada approvals found for this drug. | |||||
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| MYOVIEW 230 microgramos EQUIPO DE REACTIVOS PARA PREPARACION RADIOFARMACEUTICA | Ge Healthcare Bio-Sciences, S.A.U. | 65010 | EQUIPO DE REACTIVOS PARA PREPARACIÓN RADIOFARMACÉUTICA | Uso Hospitalario | Commercialized |
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.